These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8928074)

  • 1. [The extratumor mechanisms of osteolysis in multiple myeloma and the means for their correction].
    Golenkov AK; Lutskaia TD; Kliushnenkova EN; Tishenina RS; Valiulina LS; Novikov VE; Mitina TA
    Ter Arkh; 1996; 68(7):58-61. PubMed ID: 8928074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of clodronate on bone density in patients with multiple myeloma--a 2-year follow-up of therapeutic effects].
    Adam Z; Prokes B; Znojĭl V; Vorlícek J; Hejlová N; Hájek D; Krejcí M
    Vnitr Lek; 1996 Jun; 42(6):379-85. PubMed ID: 8928406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
    Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
    Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
    Ciepłuch H; Baran W; Hellmann A
    Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
    Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of interleukin-6 levels in the bone marrow of multiple myeloma patients with disease severity and clonogenicity in vitro.
    Bell JB; Montes A; Gooding R; Riches P; Cunningham D; Millar BC
    Leukemia; 1991 Nov; 5(11):958-61. PubMed ID: 1961036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
    Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Salmon calcitonin in supportive therapy of neoplastic osteolysis. Preliminary report on a case of myeloma].
    Andriani A; Beni A; Beni RA; Calistri A; Gelli GF
    Clin Ter; 1981 Jan; 96(2):183-91. PubMed ID: 7237953
    [No Abstract]   [Full Text] [Related]  

  • 14. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
    Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
    Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
    Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The affection of bisphosphonates combined with chemotherapy on bone metabolism index in multiple myeloma].
    Zhang X; Chang CK; Wu LY; Zhang Z; Zhou LY; Xiao C; Li X
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):660-3. PubMed ID: 22339822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Both myeloma cells and bone marrow stromal cells are involved in the overproduction of interleukin 6 in multiple myeloma].
    Ding S; Hou J; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jun; 19(6):306-8. PubMed ID: 11243111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.